Galván GE, Palacios RJM, Ficker LGB, Jiménez TO, Díaz LGE, Baena SE, Acuña MVH, Fong PM, De la Cruz OR, Ruiz OJ, Cantú RS, Medellín MB

Language: Spanish
References: 13
Page: 5-9
PDF size: 193.48 Kb.

ABSTRACT

With the introduction of the medicated stent (SM) in the coronary intervention has been a notable decrease in the rate of restenosis and reintervention. Objective: Knowing the safety and effectiveness in the use of SM in our population. Material and methods: This is an observational, descriptive and retrospective study, that analyzes the database of angioplasty of hemodynamics lab in the UMAE 34 from March 2004 to June 2007 comparing the safety and effectiveness of the SM respect to conventional stent (SNM). Results: Included 1,312 patients, SNM in 897 and SM in 415. In most one stent was implanted, the average length and diameter was 18.9 mm and 3.2 mm in SNM and 24.1 mm and 3.1 mm for SM. The lesions were more complex in the SM group. The outcome to 6 months shows statistically significant difference in TLR (2.78% SNM vs 1% SM p ‹ 0.03) and TVR (4% SNM vs 2% SM p ‹ 0.05), no differences in heart attack, death or bypass surgery. Conclusions: Even with the limitations of the study can conclude that the use SM is safe, and relates to a lower rate of TVR with respect to SNM; however it is important to review the long-term results.

REFERENCES

1. Popma JJ, Tulli M. Drug-Eluting Stents. Cardiol Clin 2006; 24: 217-231.

2. Eisenberg MJ, Konnyu KJ. Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis. Am J Cardiol 2006; 98: 375-382.

3. Lemos PA, Serruys PW, van Domburg RT, Saia F, Aramptzis CA, Hoye A et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the «real world». The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry. Circulation 2004: 109 [Epub].

4. Qasim A, Cosgrave J, Latib A, Colombo A. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications. Am J Cardiol 2007; 100: 1619-1624.

5. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, et al. Safety and efficacy of sirolimus and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.

6. Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, et al. «Off-label» stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2008; 51: 607-614.

7. Brodie BR, Stuckey T, Downey W, Humphrey A, Bradshaw B et al. Outcomes and complications with off-label use of drug-eluting stents results from the STENT (Strategic Transcatheter Evaluation of New Therapies) Group. J Am Col Cardiol Int 2008; 1; 405-414.

8. Kastrati A, Mehilli J, Pache J et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-1039.

9. De la Torre-Hernández JM, Alfonso F, Hernandez F, Elizaga J, Sanmartin M et al. Drug-eluting stent thrombosis results from the multicenter spanish registry ESTROFA (Estudio español sobre trombosis de stents farmacoactivos). J Am Coll Cardiol 2008; 51: 986-990.

10. Mauri L, Wen-hua H, Massaro JM, Kalon KLH, D’Agostino R et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029.

11. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM et al. Lack of neointimal proliferation after implantation of sirolimus coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103: 192-195.

12. Weissman NJ, Koglin J, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT et al. Polymer-based paclitaxel-eluting stents reduce in stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005; 45: 1201-1205.

13. Zahn R, Hamm CW, Schneider S, Zeymer U, Nienaber CA, Richardt G et al. German Cypher stent Registry. Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter German Cypher stent Registry). Am J Cardiol 2005; 95: 1302-1308.